PALB2 and pancreatic neoplasm: The efficacy of platinum agents for pancreatic cancer with a germline BRCA/PALB2 mutation and of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, as maintenance therapy after first-line platinum-based chemotherapy for pancreatic cancer with germline BRCA1/2 have been shown [64,65].